Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 230 of 6351
-
Can a radioactive 'Smart Bomb' shrink resistant prostate tumors?
Disease control OngoingPSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.
Phase 1 • Sponsor: Osaka University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a drug replace surgery for some colon cancers?
Disease control OngoingTo learn if cemiplimab can help to control dMMR colon cancer.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New shot could ease painful skin condition
Disease control CompletedThis is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matc…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for Hard-to-Treat lymphoma: golidocitinib faces final test
Disease control Recruiting nowThis is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically co…
Phase 3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New stroke trial combines clot removal with stenting to save brain function
Disease control Recruiting nowThe primary objective is to establish the efficacy of intra-arterial (IA) mechanical thrombectomy (MT) with extracranial proximal carotid artery acute stenting versus non-stenting approaches in patients with acute ischemic stroke (AIS) from intracranial vessel occlusion (IVO) in …
Phase 3 • Sponsor: Mercy Health Ohio • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can a new pill tame the immune System's attack after stem cell transplants?
Disease control Recruiting nowThis is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New combo attack on tough lymphoma: two immune therapies join forces
Disease control Recruiting nowTo learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new pill shrink the spleen in myelofibrosis?
Disease control OngoingThis trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose flonoltinib maleate tablet group, high-do…
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for stomach cancer: phase 3 trial of MK-2870 launches
Disease control OngoingThis study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a pill replace the CPAP machine for sleep apnea?
Disease control CompletedThe goal of this randomised, double-blind phase II/III clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive sleep apnoea who are intolerant, non-compliant, or naïve to positive airway pressure. Phase II study will be a 4-week dose-findin…
Phase 2/3 • Sponsor: Incannex Healthcare Ltd • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Which ablation method wins for tough atrial fibrillation cases?
Disease control Recruiting nowThis is a prospective, single-center, open-label, randomized controlled trial comparing thoracoscopic surgical ablation with percutaneous endocardial catheter ablation as the first rhythm-control procedure in patients with persistent atrial fibrillation and an enlarged left atriu…
Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Electric zaps to the gut could help control type 2 diabetes
Disease control OngoingThis study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Sponsor: Endogenex, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for advanced breast cancer: experimental drug BL-B01D1 takes on chemo
Disease control OngoingThis trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after failure of at least one prior line of chemotherapy…
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a targeted drug hit the mark against HER2-mutated lung cancer?
Disease control OngoingThis phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New triple therapy shows promise for tough liver cancers
Disease control Recruiting nowThis study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of resectable hepatocellular carcinoma with portal vein…
Phase 2 • Sponsor: Yongyi Zeng • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could a gentle brain zapper curb opioid cravings?
Disease control Recruiting nowInvestigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I,…
Sponsor: Butler Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can three common drugs boost chemotherapy against pancreatic cancer?
Disease control Recruiting nowThe goals of this trial are: 1) To evaluate the safety and tolerability of C3 administration with Gemcitabine; and 2) To assess the disease response following C3 administration with Gemcitabine. The main question it aims to answer are: 1) Is C3 in combination with Gemcitabine saf…
Phase 1/2 • Sponsor: State University of New York - Downstate Medical Center • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New catheter aims to save limbs when all else fails
Disease control By invitation onlyThe purpose of this study is to establish the safety and effectiveness of the Boomerang Catheter for percutaneous Deep Venous Arterialization (pDVA) to treat no-option Chronic Limb-Threatening Ischemia.
Sponsor: Aveera Medical, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Stroke drug tirofiban may boost recovery after clot removal
Disease control CompletedAcute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current…
Phase 2/3 • Sponsor: Xiang Luo • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo aims to stop lung cancer return after surgery
Disease control Recruiting nowThis study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior t…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC